---
title: 'DICE, Odyssey, Fred Hutch, Merck (MSD)'
type: 'episode'
url: 'https://doc.social/episodes/dice-odyssey-fred-hutch-merck-msd'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-10-18'
audio: 'unavailable — the host retired the file'
---

# DICE, Odyssey, Fred Hutch, Merck (MSD)

One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesDICEOdysseyFred HutchMerck (MSD), Merck Story 2About the Sho…

## Summary

One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References**
[DICE](https://investors.dicetherapeutics.com/news-releases/news-release-details/dice-announces-pricing-upsized-public-offering-common-stock)
[Odyssey](https://www.biospace.com/article/odyssey-therapeutics-bags-168-million-in-series-b-one-year-after-218-million-series-a-/)
[Fred Hutch
](https://endpts.com/new-look-fred-hutch-snags-slice-of-bezos-fortune-for-10-years-of-research/)[Merck (MSD)](https://investors.modernatx.com/news/news-details/2022/Merck-and-Moderna-Announce-Exercise-of-Option-by-Merck-for-Joint-Development-and-Commercialization-of-Investigational-Personalized-Cancer-Vaccine/default.aspx), [Merck Story 2](https://www.biospace.com/article/merck-s-sotatercept-shows-stellar-performance-in-phase-iii/?s=61)**
**
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.